Navigation Links
Arpida to Discuss Strategy With Shareholders

REINACH, Switzerland, May 7 /PRNewswire-FirstCall/ -- Arpida Ltd. (SIX: ARPN) will today discuss potential strategic scenarios with its shareholders during the Annual General Meeting (AGM) which starts at 10am CET in Reinach, Switzerland.

After the negative FDA opinion regarding intravenous iclaprim, Arpida has initiated a thorough analysis with the aim to design a roadmap towards approval. The company was supported by international experts in this field.

As Arpida lacks both the time and the money to complete this path, a search for funding or other strategic options took place in parallel. The search for fresh funds did not yield any results as access to credit lines or equity funding is not available.

During the last months, Arpida, supported by external advisors, has explored all other strategic scenarios, including 'reverse mergers', takeovers, asset sales as well as liquidation as a last resort.

Board and Management currently pursue business development contacts with 72 companies, both inside Switzerland and abroad. Of these, Arpida focuses on 5 that have advanced into negotiations which are currently ongoing. At today's meeting no vote is planned on this item, as no concrete proposal is available at this time. If and when a major strategic proposal is made, shareholders will obviously be duly involved.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

    Arpida contacts:

    Dr Jurgen Raths, President and CEO,Tel: +41-61-417-96-60;
    Harry Welten, MBA, CFO and Senior Vice President,Tel: +41-61-417-96-65;
    Paul Verbraeken, Head of Corporate Communications,Tel: +41-61-417-96-83.

SOURCE Arpida Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arpida Announces Full Year 2008 Financial Results
2. Arpida to Restructure and Focus on Key Projects
3. Arpidas iclaprim MAA Accepted for Review by EMEA
4. Arpida Reports Interim Results for Six Months to 30 June 2008
5. Arpida Announces FDA Acceptance of the Iclaprim New Drug Application
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company
8. Arpida Announces Conference Call on 17 April
9. Arpida Announces Agenda Items for Shareholders Meeting
10. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
11. Arpida Announces Full Year 2007 Financial Results
Post Your Comments:
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
Breaking Biology Technology:
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):